EUVIMEDEUVIMED entdecken
Metaanalyse

Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis

Jack M Lawrence iD, Manya Mirchandani, Andrew Hill

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkac440 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Jack M Lawrence und 2 weiteren Autor:innen. Beteiligte Einrichtung: St George's, University of London, London, UK. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: International Treatment Preparedness Coalition/Make Medicines Affordable Campaign.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In response to the COVID-19 pandemic, Merck Sharp & Dohme (MSD) acquired the global licensing rights for the antiviral molnupiravir, promising affordable access via licensing deals. Numerous Indian pharmaceutical companies subsequently conducted trials of the drug. Registered trials of molnupiravir were searched on the Clinical Trials Registry–India (CTRI) and efforts made to detect resulting public data. Per the CTRI, 12 randomized trials of molnupiravir were conducted in 13 694 Indian patients, from mid-2021. By August 2022, only a preprint and medical conference presentation had resulted. Additionally, two trials were mentioned in press releases suggesting failure of treatment. The available data contain unexplained results that differ significantly from both the PANORAMIC and MSD MOVe-OUT trials. Approximately one-third of the global data on molnupiravir remain unpublished. We conducted a meta-analysis with four studies that provided results and observed that molnupiravir does not have a significant benefit for hospitalizations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansPublication BiasPandemicsSARS-CoV-2Antiviral AgentsCytidineHydroxylamines

Substanzen

Antiviral AgentsmolnupiravirCytidineHydroxylamines

Autor:innen und Institutionen

  • St George's, University of London, London, UK.
  • Faculty of Medicine, Imperial College London, London, UK.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

ORCID-Profile: Jack M Lawrence

Förderung

  • International Treatment Preparedness Coalition/Make Medicines Affordable Campaign

Zitieren

APA

Lawrence, J. M., Mirchandani, M., & Hill, A. (2023). Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac440

Vancouver

Lawrence JM, Mirchandani M, Hill A. Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac440

BibTeX
@article{Lawrence2023,
  author = {Lawrence, Jack M and Mirchandani, Manya and Hill, Andrew},
  title = {Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkac440}
}
Kostenlos starten →